Overview

Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetics, pharmacodynamics and safety of multiple doses of the NVA237 in mild and moderate COPD patients .
Phase:
Phase 1
Details
Lead Sponsor:
Novartis
Treatments:
Glycopyrrolate